QUOTES.
Anthony Quinn
" We are pleased that the FDA designated sebelipase alfa as Breakthrough Therapy for patients with early onset LAL Deficiency, or Wolman disease "
May-21,2013
Steven King
" This agreement on a Phase III trial design with the FDA is a critical milestone for the bavituximab program ... We will now focus on starting the Phase III trial while continuing ongoing partnering discussions. With immunotherapies at the forefront of new approaches to treating cancer, we are well positioned with bavituximab's novel immune activation mechanism to help advance this rapidly evolving field. "
May-20,2013
